Zobrazeno 1 - 10
of 15
pro vyhledávání: '"J F Dahlerup"'
Autor:
M Attauabi, J F Dahlerup, A Poulsen, M R Hansen, M K Vester-Andersen, S Eraslan, A P Prahm, N Pedersen, L Larsen, T Jess, A Neumann, K V Haderslev, A Molazahi, A B Lødrup, H Glerup, A M Oppfeldt, M D Jensen, K Theede, M Kiszka-Kanowitz, J B Seidelin, J Burisch
Publikováno v:
Journal of Crohn's and Colitis. 16:i562-i565
Background The coronavirus disease 2019 (COVID-19) pandemic raised concerns among patients with ulcerative colitis (UC) and Crohn’s disease (CD) fearing an increased susceptibility to infection and increased risk of poor outcomes. Furthermore, the
Autor:
M Attauabi, J F Dahlerup, A Poulsen, M R Hansen, M K Vester-Andersen, S Eraslan, A P Prahm, N Pedersen, L Larsen, T Jess, A Neumann, K V Haderslev, A Molazahi, A B Lødrup, H Glerup, A M Oppfeldt, M D Jensen, K Theede, M Kiszka-Kanowitz, J B Seidelin, J Burisch
Publikováno v:
Journal of Crohn's and Colitis. 16:i072-i074
Background The vast majority of patients with ulcerative colitis (UC) and Crohn’s disease (CD) who acquire coronavirus disease 2019 (COVID-19) survive the infection. Still, the long-term health consequences of COVID-19 are not well described in pat
Autor:
M Attauabi, J F Dahlerup, A Poulsen, M Rosager Hansen, M K Vester-Andersen, S Eraslan, A P Prahm, N Pedersen, L Larsen, T Jess, A Neumann, K V Haderslev, A Molazahi, A B Lødrup, H Glerup, A M Oppfeldt, M D Jensen, K Theede, M Kiszka-Kanowitz, J B Seidelin, J Burisch
Publikováno v:
Journal of Crohn's and Colitis. 16:i587-i589
Background Population-based data regarding outcomes of coronavirus disease 2019 (COVID-19) among patients with ulcerative colitis (UC) and Crohn’s disease (CD) remain limited. Methods We conducted a population-based study investigating the outcomes
Autor:
S. H. Overgaard, S. Sorensen, H. L. Munk, A. B. Nexøe, H. Glerup, R. H. Henriksen, T. Guldmann, N. Pedersen, S. Saboori, L. Hvid, J. F. Dahlerup, C. L. Hvas, M. Jawhara, K. W. Andersen, A. Kristian Pedersen, O. H. Nielsen, F. H. Bergenheim, J. B. Brodersen, B. L. Heitmann, T. I. Halldorsson, U. Holmskov, A. Bygum, R. Christensen, J. Kjeldsen, T. Ellingsen, V. Andersen
Publikováno v:
Annals of the Rheumatic Diseases. 81:592-593
BackgroundCrohn’s disease (CD), Ulcerative Colitis (UC), Rheumatoid Arthritis (RA), Axial Spondyloarthritis (axSpA), Psoriatic Arthritis (PsA), and Psoriasis (PsO) are known as Chronic Inflammatory Diseases (CID). These CID’s are prevalent diseas
Autor:
M Attauabi, J F Dahlerup, A Poulsen, M R Hansen, M K Vester-Andersen, S Eraslan, A P Prahm, N Pedersen, L Larsen, T Jess, A Neumann, K V Haderslev, A Molazahi, A B Lødrup, H Glerup, A M Oppfeldt, M D Jensen, K Theede, M Kiszka-Kanowitz, J B Seidelin, J Burisch
Publikováno v:
Journal of Crohn's and Colitis. 16:i071-i072
Background Whether the disease activity of ulcerative colitis (UC) and Crohn’s disease (CD) is correlated with the severity of coronavirus disease 2019 (COVID-19) remains poorly investigated with only few selected cohort studies having addressed th
Autor:
P, Bager, R, Befrits, O, Wikman, S, Lindgren, B, Moum, H, Hjortswang, N H, Hjollund, J F, Dahlerup
Publikováno v:
Alimentary pharmacologytherapeutics. 35(1)
Patients with inflammatory bowel disease (IBD) often complain of fatigue.To investigate the prevalence and characteristics of fatigue among IBD out-patients in Scandinavia and to provide normative values for fatigue in IBD patients.A cross-sectional
Publikováno v:
Alimentary pharmacologytherapeutics. 32(11-12)
Vitamin D3 has shown immune-modulating effects in CD4+ T cells from Crohn's disease patients in vitro.To investigate the effects of in vivo vitamin D3 treatment on T cells in Crohn's disease patients.Peripheral blood mononuclear cells (PBMC) were iso
Autor:
S P, Jørgensen, J, Agnholt, H, Glerup, S, Lyhne, G E, Villadsen, C L, Hvas, L E, Bartels, J, Kelsen, L A, Christensen, J F, Dahlerup
Publikováno v:
Alimentary pharmacologytherapeutics. 32(3)
Vitamin D has immune-regulatory functions in experimental colitis, and low vitamin D levels are present in Crohn's disease.To assess the effectiveness of vitamin D3 treatment in Crohn's disease with regard to improved disease course.We performed a ra
Publikováno v:
Clinical and experimental immunology. 138(1)
Integrin alpha4beta 7 is the principal gut-homing receptor, and it is assumed that expression of this specific integrin directs lymphocytes to the gut in vivo. Adoptive cellular immunotherapy against inflammatory bowel disease (IBD) may depend on the
Publikováno v:
Alimentary pharmacologytherapeutics. 19(11)
Azathioprine is effective for maintenance of remission in Crohn's disease, however, duration of efficacy and the dose response relationship has not been fully evaluated.To investigate whether patients kept in remission by azathioprine treatment for2